ClinicalTrials.gov
ClinicalTrials.gov Menu

The neoClose Abdominal Closure vs Carter-Thomason Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02589171
Recruitment Status : Recruiting
First Posted : October 28, 2015
Last Update Posted : October 26, 2016
Sponsor:
Collaborator:
NeoSurgical Limited
Information provided by (Responsible Party):
Peter Walker, The University of Texas Health Science Center, Houston

Brief Summary:
The purpose of this study is to compare the neoClose abdominal closure to the standard Carter-Thomason closure in a bariatric surgery gastric bypass population.

Condition or disease Intervention/treatment Phase
Surgical Port Site Hernia Device: Neo Close Abdominal Closure Device: Carter Thomason Device Not Applicable

Detailed Description:
Both the neoClose abdominal closure to the standard Carter-Thomason closurewill be used to close 12 mm camera and stapler port sites upon completion of a robotic assisted laparoscopic gastric bypass. The procedure requires a 12 mm port be placed in the midline approximately 3 cm cephalad to the umbilicus and a second in the right mid abdomen. Port sites will be closed as defined as the inability to palpate a fascial defect and the incision being air tight upon carbon dioxide insufflation.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Randomized Trial Evaluating Effectiveness of neoClose Abdominal Closure Device Versus Carter-Thomason Needle Passer
Study Start Date : February 2016
Estimated Primary Completion Date : November 2017
Estimated Study Completion Date : November 2017

Arm Intervention/treatment
Experimental: Neo Close Abdominal Closure Device: Neo Close Abdominal Closure
Neo Close Abdominal Closure
Active Comparator: Carter Thomason Device Device: Carter Thomason Device
Carter Thomason Device



Primary Outcome Measures :
  1. Technical effectiveness as assessed by number of sutures required to complete closure [ Time Frame: at the time of surgery ]
  2. Technical effectiveness as assessed by the time required to complete closure [ Time Frame: at the time of surgery ]
  3. Technical effectiveness as assessed by depth of needle penetration to complete closure [ Time Frame: at the time of surgery ]
  4. Technical effectiveness as assessed by surgical site occurrences [ Time Frame: immediately post op ]
    Surgical site occurrences include hernia and infection.

  5. Technical effectiveness as assessed by surgical site occurrences [ Time Frame: 1 week ]
    Surgical site occurrences include hernia and infection.

  6. Technical effectiveness as assessed by surgical site occurrences [ Time Frame: 6 weeks ]
    Surgical site occurrences include hernia and infection.

  7. Technical effectiveness as assessed by presence of port site hernia [ Time Frame: 6 weeks ]
    Abdominal ultrasound will be used to detect port site hernia.


Secondary Outcome Measures :
  1. Pain as assessed by a visual analog scale at the 12mm camera port site [ Time Frame: immediately after surgery ]
  2. Pain as assessed by a visual analog scale at the 12mm camera port site [ Time Frame: 1 week ]
  3. Pain as assessed by a visual analog scale at the 12mm camera port site [ Time Frame: 6 weeks ]
  4. Pain as assessed by a visual analog scale at the stapler port site [ Time Frame: immediately after surgery ]
  5. Pain as assessed by a visual analog scale at the stapler port site [ Time Frame: 1 week ]
  6. Pain as assessed by a visual analog scale at the stapler port site [ Time Frame: 6 weeks ]
  7. Pain assessed by amount of intravenous narcotics required immediately after surgery [ Time Frame: immediately after surgery ]
  8. Pain as assessed by amount of intravenous narcotics required one day after surgery [ Time Frame: 1 day after surgery ]
  9. Pain as assessed by hospital stay duration [ Time Frame: immediately after surgery ]
  10. Pain as assessed by hospital stay duration [ Time Frame: 1 day after surgery ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Morbid obesity (BMI > 35).
  • Completed multimodality pre operative evaluation (Psychology, Nutrition, Support Groups).
  • Approved for robotic assisted laparoscopic gastric bypass.

Exclusion Criteria:

  • Previous midline laparotomy or weight loss procedure.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02589171


Contacts
Contact: Peter Walker, MD (713) 892-5500 Peter.A.Walker@uth.tmc.edu
Contact: Angielyn Rivera (713) 486-1350 Angielyn.R.Rivera@uth.tmc.edu

Locations
United States, Texas
The University of Texas Health Science Center at Houston Recruiting
Houston, Texas, United States, 77030
Contact: Peter Walker, MD    713-892-5500    Peter.A.Walker@uth.tmc.edu   
Sponsors and Collaborators
The University of Texas Health Science Center, Houston
NeoSurgical Limited
Investigators
Principal Investigator: Peter Walker, MD The University of Texas Health Science Center, Houston

Responsible Party: Peter Walker, Assistant Professor, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier: NCT02589171     History of Changes
Other Study ID Numbers: HSC-MS-15-0668
First Posted: October 28, 2015    Key Record Dates
Last Update Posted: October 26, 2016
Last Verified: October 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes